Globus Medical (NYSE:GMED) Announces Quarterly Earnings Results

Globus Medical (NYSE:GMED) released its quarterly earnings data on Tuesday. The medical device company reported $1.28 EPS for the quarter, beating the consensus estimate of $1.06 by $0.22, Zacks reports. The business had revenue of $826.42 million for the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The business’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.84 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Record financial finish: Globus reported FY2025 revenue of $2.939 billion (+16.7%) and non-GAAP EPS of $3.98 (+30.8%), with Q4 revenue of $826.4 million (+25.7%) and non-GAAP EPS of $1.28 (+52.1%).
• Base business momentum and product execution: Legacy Globus base revenue grew 10.6% in Q4 (U.S. spine ~10% and 48 weeks of consecutive growth), supported by multiple spine product launches and record Enabling Technologies sales (EGPS/Excelsius pipeline closures).
• Nevro integration moving faster than planned: Nevro added $293.6M for the year ($99.7M in Q4), reached a 21.2% Adjusted EBITDA margin in Q4, and was EPS-accretive within nine months—though management warns near-term lumpiness during integration.
• Synergies and margin expansion driving guidance lift: Globus has realized $200M of NuVasive synergies ahead of plan, adjusted gross margin improved to 69.2% in Q4, and management raised FY2026 EPS guide to $4.40–$4.50 while reiterating revenue guidance of $3.18–$3.22 billion.
• Operational headwinds and near-term risks: Enabling-technology deals were lumpy with elongated pipelines, international growth faced supply-chain and APAC softness earlier in 2025, and cash fell after debt paydown, the Nevro purchase, and ~$300M of buybacks—creating short-term execution and liquidity considerations.

Globus Medical Stock Down 1.5%

GMED stock opened at $92.01 on Wednesday. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40. The firm has a 50-day simple moving average of $90.10 and a 200-day simple moving average of $75.84. The stock has a market capitalization of $12.31 billion, a P/E ratio of 29.68, a P/E/G ratio of 1.43 and a beta of 1.06.

Analysts Set New Price Targets

A number of research firms have weighed in on GMED. TD Cowen upgraded Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. BTIG Research restated a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Needham & Company LLC raised shares of Globus Medical from a “hold” rating to a “buy” rating and set a $112.00 target price for the company in a report on Friday, January 30th. Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up from $93.00) on shares of Globus Medical in a research note on Tuesday, November 18th. Finally, Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and a consensus target price of $100.18.

Insiders Place Their Bets

In other news, EVP Kelly Huller sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $87.67, for a total value of $876,700.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Leslie V. Norwalk sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the sale, the director owned 10,419 shares of the company’s stock, valued at $1,053,360.90. The trade was a 16.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 34,136 shares of company stock worth $3,111,033. Corporate insiders own 18.54% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its position in Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after buying an additional 3,595,339 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in shares of Globus Medical by 87.4% in the 4th quarter. Corient Private Wealth LLC now owns 89,916 shares of the medical device company’s stock worth $7,851,000 after acquiring an additional 41,934 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Globus Medical in the 4th quarter worth approximately $499,000. EP Wealth Advisors LLC purchased a new position in shares of Globus Medical during the 4th quarter worth approximately $607,000. Finally, Fuller & Thaler Asset Management Inc. acquired a new stake in Globus Medical in the 4th quarter valued at approximately $90,411,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q4 revenue and adjusted results beat expectations — Globus reported Q4 net sales of $826.4M (+25.7% YoY) and strong adjusted EBITDA/non‑GAAP EPS, driven in part by the Nevro contribution and base business strength. GlobeNewswire Release
• Positive Sentiment: Raised non‑GAAP EPS guidance for 2026 and reconfirmed revenue range — management updated 2026 non‑GAAP EPS to $4.40–$4.50 and reaffirmed revenue of $3.18–$3.22B, signalling confidence in integration and margin leverage. Guidance / Release
• Positive Sentiment: Profitability expansion — company posted record non‑GAAP EPS and sizable increases in gross profit and operating profit, reflecting synergies from acquisitions and cost discipline. Quiver Quant Summary
• Neutral Sentiment: Investor materials and call scheduled — management held a conference call and published detailed GAAP/non‑GAAP reconciliations; listen/transcript available for further color on sustainability of margins. Press Release / Call Materials
• Neutral Sentiment: Wide analyst interest and price‑target dispersion — multiple firms maintain buy/overweight ratings with median targets near $100, but targets vary, so consensus reaction may diverge. Quiver – Analyst Snapshot
• Negative Sentiment: GAAP vs non‑GAAP earnings confusion — GAAP diluted EPS was $1.03 while non‑GAAP EPS was $1.28; some outlets reported an EPS “miss” on GAAP or different consensus metrics, creating headline risk and mixed press coverage. Quiver – EPS Detail
• Negative Sentiment: Growth concentrated in recent acquisitions — base business (ex‑Nevro) grew only ~5% for the year, raising questions about how much of future upside will rely on further M&A versus organic acceleration. Quiver – Business Mix
• Negative Sentiment: Cash and capital deployment concerns plus insider selling — cash and equivalents fell to ~$526M, capex and acquisitions were sizable, and recent insider sales were noted by data providers, which can pressure sentiment. Quiver – Cash & Insider Activity

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.